Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

Core Insights - Rhythm Pharmaceuticals reported a net product revenue of $57.3 million from global sales of IMCIVREE for Q4 2025, marking a 12% increase from Q3 2025, driven by sales for Bardet-Biedl syndrome (BBS) and an increase in reimbursed therapy patients globally [1][6][8] - The company is focused on long-term growth and is well-capitalized to achieve important commercial and clinical milestones, including the potential launch of IMCIVREE for acquired hypothalamic obesity (HO) pending FDA approval [2][5] Recent Business Highlights - IMCIVREE revenue for Q4 2025 was $57.3 million, with $39.0 million (68%) generated in the U.S. and $18.3 million (32%) from international sales, the latter showing a 40% sequential increase [6][8] - The company entered into Product Listing Agreements in Canada for public reimbursement of IMCIVREE for weight management in eligible patients with BBS and obesity [6] - Rhythm completed a positive end-of-Phase-2 meeting with the FDA regarding bivamelagon in acquired HO, showing promising BMI reduction data [6][12] Clinical Development Highlights - The company is on track to report topline data from a 12-patient Japanese cohort of the setmelanotide Phase 3 trial in acquired HO in March 2026 [5][12] - Anticipated milestones include the initiation of a pivotal Phase 3 trial for bivamelagon in acquired HO by year-end 2026 [5][12] Financial Performance - For the full year 2025, net product revenues were $194.8 million, compared to $130.1 million in 2024 [8] - R&D expenses for Q4 2025 were $42.0 million, a slight increase from $41.2 million in Q4 2024, while full-year R&D expenses decreased to $167.3 million from $238.0 million in 2024 [9] - SG&A expenses rose to $57.5 million for Q4 2025, up from $38.1 million in Q4 2024, primarily due to increased headcount and marketing costs [10] Cash Position - As of December 31, 2025, the company had cash, cash equivalents, and short-term investments of approximately $388.9 million, an increase from $320.6 million as of December 31, 2024 [7][15]